---
document_datetime: 2023-09-21 21:24:23
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/vihuma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: vihuma-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.7590847
conversion_datetime: 2025-12-30 22:36:27.623933
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Vihuma

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| WS/2244              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of study results of study GENA-21b; a prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalised prophylaxis with Human-cl rhFVIII in previously | 13/10/2022                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | treated adult patients with severe haemophilia A to update the Adverse Drug Reactions in section 4.8 of the SmPC, based on reports from clinical trials. Section 5.1 of the SmPC has been updated to provide in-formation on a prospective open-label clinical study. For more information, please refer to the Summary of Product Characteristics. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |     |       |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------|
| WS/2319   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                                                                    | 01/09/2022 | n/a |       |
| IG/1527/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits Administrative change - Change in the name                                                                             | 22/06/2022 | n/a | A.4 - |

<div style=\"page-break-after: always\"></div>

|         | and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.e.2.b - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)   |            |     |                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2156 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Submission of the final report from study GENA-99 including the integrated analysis report of studies GENA-99, GENA-13, GENA-15, GENA-21, GENA-21b and GENA-100. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                 | 27/01/2022 | n/a | This variation includes the submission of the final reports from study GENA-99 including the integrated analysis report of studies GENA-99, GENA-13, GENA-15, GENA-21, GENA-21b and GENA-100 to provide data on the long-term immunogenicity, safety, and efficacy of simoctocog alfa in patients with haemophilia A in line with the requirements of the FVIII guideline. Please also refer to Scientific Discussion 'Nuwiq-Vihuma- WS-2156' |
| WS/2064 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 02/12/2021 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                  |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/2146             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS | 07/10/2021 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| R/0026              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                        | 22/07/2021 | 22/09/2021 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Vihuma in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. No changes in the PI have been considered necessary based on the data provided in the renewal applica-tion. Nevertheless, changes in the PI have been included in the SmPC and in annex IIIB to align the wording with the excipient guideline for sodium content, to delete the additional monitoring text (inverted black triangle) and to align the text to the latest QRD review |
| PSUSA/10276 /202101 | Periodic Safety Update EU Single assessment - simoctocog alfa                                                                                                                                                                                                                                                                                                                                  | 02/09/2021 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| WS/2029   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e.1.z - Change in immediate packaging of the finished product - Other variation                                                                                                                                                  | 18/03/2021   | n/a   |           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------|
| WS/1999   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS                    | 04/03/2021   | n/a   |           |
| WS/1992/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other | 14/01/2021   | n/a   | variation |
| IG/1310/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                  | 27/11/2020   | n/a   |           |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits           |            |            |                                  |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| WS/1847 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                         | 16/07/2020 | 09/07/2021 | SmPC, Annex II, Labelling and PL |
| WS/1816 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                       | 02/07/2020 | n/a        |                                  |
| WS/1752 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 30/01/2020 | n/a        |                                  |

<div style=\"page-break-after: always\"></div>

| WS/1726             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS   | 28/11/2019   | n/a   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| WS/1662             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                        | 12/09/2019   | n/a   |                                   |
| PSUSA/10276 /201901 | Periodic Safety Update EU Single assessment - simoctocog alfa                                                                                                                                                                                                                                                                                                                                    | 05/09/2019   | n/a   | PRAC Recommendation - maintenance |
| IG/1138/G           | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation                                                                                           | 26/08/2019   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

| WS/1506/G   | application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance   | 25/07/2019   | 17/07/2020   | SmPC and PL            | This was an data    |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|---------------------|
| WS/1584     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New and/or WCB                                                                                                            | 20/06/2019   | n/a          |                        | storage site of MCB |
| IG/1061     | B.IV.1.a.1 - Change of a measuring or administration device - Addition or replacement of a device which is not an integrated part of the primary packaging - Device with CE marking                                                                                                                                                                                          | 31/01/2019   | n/a          |                        |                     |
| X/0006/G    | This was an application for a group of variations. Annex I_2.(c) Change or addition of a new strength/potency C.I.1.b - Change(s) in the SPC, Labelling or PL                                                                                                                                                                                                                | 18/10/2018   | 20/12/2018   | SmPC, Labelling and PL |                     |

<div style=\"page-break-after: always\"></div>

|         | intended to implement the outcome of a Union referral procedure - The product is not covered by the defined scope of the procedure but the change(s) implements the outcome of the procedure and no new additional data is required to be submitted by the MAH C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/1427 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                         | 25/10/2018 | n/a |
| WS/1404 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch                                                                                                                                                                                                                                                                                                                                                                                  | 18/10/2018 | n/a |

<div style=\"page-break-after: always\"></div>

|                     | control/testing takes place and any of the test method at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| WS/1425             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 13/09/2018 | n/a |                                   |
| PSUSA/10276 /201801 | Periodic Safety Update EU Single assessment - simoctocog alfa                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 06/09/2018 | n/a | PRAC Recommendation - maintenance |
| IG/0969/G           | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - | 03/08/2018 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | Replacement/addition of a site where batch control/testing takes place B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                               |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| WS/1176/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol | 28/09/2017 | n/a |

<div style=\"page-break-after: always\"></div>

| II/0001/G   | This was an application for a group of variations.   | 20/07/2017   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|